Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advertisement
Emily MenendezMuscle Invasive Urothelial Carcinoma | September 8, 2023
Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.
Read More
Guru P. Sonpavde, MDMuscle Invasive Urothelial Carcinoma | August 24, 2023
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Ajitha Kommalapati, MDASCO 2023 | August 15, 2023
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
Raj Satkunasivam, MD, MS, FRCSCMuscle Invasive Urothelial Carcinoma | August 9, 2023
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
Emily MenendezMuscle Invasive Urothelial Carcinoma | July 28, 2023
The COXEN model is used to select genes for predicting tumor cell response to a specific drug treatment.
Zachary BessetteASCO 2023 | June 5, 2023
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Matthew Deek, MDASCO 2023 | June 4, 2023
Dr. Deek highlights his analysis of NRG RTOG 0524 and 0712 for prognostic significance of immune cell infiltration in MIBC.
Emily MenendezASCO 2023 | June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 23, 2023
Researchers compared maximal transurethral resection followed by concurrent chemoradiation with radical cystectomy.
Emily MenendezMuscle Invasive Urothelial Carcinoma | May 18, 2023
A recent exploratory analysis examined patients with MIBC who were treated with radical radiotherapy and concomitant drugs.
Akhil Abraham Saji, MDMuscle Invasive Urothelial Carcinoma | May 1, 2023
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
Zachary BessetteAUA 2023: Focus on Bladder Cancer | April 28, 2023
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
Emily MenendezAUA 2023: Focus on Bladder Cancer | April 28, 2023
TAR-200 consists of a small silicone delivery system that provides sustained, local release of gemcitabine to the bladder.
Emily MenendezMuscle Invasive Urothelial Carcinoma | March 23, 2023
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Daniel M. Geynisman, MDASCO GU Symposium 2023 | February 23, 2023
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Matthew D. Galsky, MDASCO GU Symposium 2023 | February 17, 2023
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Emily MenendezMuscle Invasive Urothelial Carcinoma | January 23, 2023
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Advertisement
Advertisement
Advertisement